Research Analysts’ Weekly Ratings Updates for Jasper Therapeutics (JSPR)

Several analysts have recently updated their ratings and price targets for Jasper Therapeutics (NASDAQ: JSPR):

• 8/18/2026 – Jasper Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 8/15/2026 – Jasper Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/12/2026 – Jasper Therapeutics is now covered by Piper Sandler. They set an “overweight” rating and a $2.00 price target on the stock.
• 8/12/2026 – Jasper Therapeutics is now covered by Piper Sandler. They set an “overweight” rating and a $2.00 price target on the stock.
• 7/25/2026 – Jasper Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 7/17/2026 – Jasper Therapeutics had its “sell (e+)” rating reaffirmed by Weiss Ratings.

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.